Literature DB >> 1342065

Dexamethasone reverses glucocorticoid receptor RNA depression in multi-drug resistant (MDR) myeloma cell lines.

L Danel-Moore1, M Brönnegard, J A Gustafsson.   

Abstract

Glucocorticoid receptors and glucocorticoid receptor RNA (GR RNA) were measured in doxorubicin resistant myeloma cell lines to investigate the relationship between multi-drug resistance and glucocorticoid sensitivity. Glucocorticoid binding sites and GR RNA were found to be lowered in all the tested doxorubicin resistant cell lines: R10, R40 and R60 compared to the untreated wild type RPMI 8226 cells (Dalton, et al., 1984). The least resistant cell line, R10, maintained a down regulation of GR RNA after 48 hours of dexamethasone (10(-6) M) treatment of the cells. Interestingly, the R10 cell line has been reported to be very sensitive to dexamethasone treatment. However, the GR RNA levels increased in presence of dexamethasone in the most resistant cell line, R40, R60 by comparison to the wild type. Thus, the reduction of GR RNA by doxorubicin treatment appears to be overcome by dexamethasone in the most resistant cell lines. Steroids may be helpful in reversing resistance and maintaining drug sensitive human tumor populations that will continue to respond to cancer chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1342065     DOI: 10.1007/bf02987757

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  25 in total

1.  Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.

Authors:  M Gomi; K Moriwaki; S Katagiri; Y Kurata; E B Thompson
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

2.  Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.

Authors:  H Kusumoto; Y Maehara; H Anai; T Kusumoto; K Sugimachi
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

3.  Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.

Authors:  A M Deffie; J K Batra; G J Goldenberg
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

4.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

5.  Positive regulation of the glucocorticoid receptor in human T-cells sensitive to the cytolytic effects of glucocorticoids.

Authors:  L P Eisen; M S Elsasser; J M Harmon
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

6.  Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas.

Authors:  L Danel; C Vincent; F Rousset; B Klein; R Bataille; M Flacher; B G Durie; J P Revillard
Journal:  J Steroid Biochem       Date:  1988       Impact factor: 4.292

7.  Complementation between glucocorticoid receptor and lymphocytolysis in somatic cell hybrids of two glucocorticoid-resistant human leukemic clonal cell lines.

Authors:  Y S Yuh; E B Thompson
Journal:  Somat Cell Mol Genet       Date:  1987-01

8.  Glucocorticoid effects on lipid lateral diffusion and membrane composition in lipopolysaccharide-activated B-cell leukemia 1 cells.

Authors:  K M Keating; B G Barisas; D A Roess
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

Review 9.  Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly.

Authors:  F Cabral; S B Barlow
Journal:  FASEB J       Date:  1989-03       Impact factor: 5.191

10.  Human calpactin II (lipocortin I) messenger ribonucleic acid is not induced by glucocorticoids.

Authors:  M Brönnegård; O Andersson; D Edwall; J Lund; G Norstedt; J Carstedt-Duke
Journal:  Mol Endocrinol       Date:  1988-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.